Skip to main content
Clinical Trials/NCT03828383
NCT03828383
Completed
Not Applicable

Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers

University of California, Berkeley5 sites in 1 country78 target enrollmentFebruary 26, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dementia
Sponsor
University of California, Berkeley
Enrollment
78
Locations
5
Primary Endpoint
Zarit Burden Interview-Short Form
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal dementia.

Detailed Description

This study aims to develop, refine, and evaluate a hardware/software system designed to integrate in-home sensors and devices, social connection, and Internet-of-Things (i.e., devices that can be controlled and communicated with via the internet) technologies to create a more supportive and safe home environment for caregivers and people with dementia. The system monitors troublesome behaviors in people with dementia (e.g., wandering), and targets mechanisms (e.g., worry, social isolation) thought to link behavioral symptoms in people with dementia with adverse caregiver outcomes (declines in health and well-being). The system is designed to minimize demands on caregivers' limited time and energy and to provide a platform for data collection that can be used by researchers and care professionals. Hypotheses: 1. Caregivers in the full operation condition will have fewer negative effects of caregiving (lower burden, higher mental and physical health, higher well-being) than those in the limited home safety condition. 2. Greater use of the social networking features of the system will be associated with fewer caregiver depressive symptoms. 3. Greater utilization of the home safety features of the system will be associated with fewer caregiver anxiety symptoms.

Registry
clinicaltrials.gov
Start Date
February 26, 2019
End Date
November 27, 2020
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Robert Levenson

Professor

University of California, Berkeley

Eligibility Criteria

Inclusion Criteria

  • Caregivers are fluent/literate in English
  • Caregivers currently reside with spouse/family member with dementia
  • Caregivers primarily use an iPhone
  • Caregiver has wireless internet in home

Exclusion Criteria

  • Caregivers providing care for individuals with known non-neurodegenerative conditions affecting behavior and cognition
  • Caregivers providing care for individuals with longstanding Axis I psychiatric disorder
  • Caregivers providing care for individuals with metabolic disorder or major organ dysfunction
  • Caregivers providing care for individuals with alcohol abuse or dependence (within 5 years of dementia onset)
  • Caregivers providing care for individuals with head trauma with loss of consciousness greater than 30 minutes
  • Caregivers providing care for individuals with contraindications to MRI imaging
  • Caregivers providing care for individuals with large confluent white matter lesions
  • Caregivers providing care for individuals with significant systemic medical illness
  • Caregivers providing care for individuals who use a medication likely to affect central nervous system functions adversely
  • If you live in the San Francisco Bay Area, Las Vegas (Clark County), Orange County, Los Angeles County, or Oregon, you may complete the following screening questionnaire to determine your eligibility for participation: https://bit.ly/UCBDC Upon completion of the screening questionnaire, the UC Berkeley research team will follow up soon after by email or phone to confirm your eligibility status.

Outcomes

Primary Outcomes

Zarit Burden Interview-Short Form

Time Frame: 9 months after baseline

Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes.

Center for Epidemiological Studies Depression Scale (CES-D)

Time Frame: 9 months after baseline

Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16.

Beck Anxiety Inventory (BAI)

Time Frame: 9 months after baseline

Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant.

Satisfaction With Life Scale

Time Frame: 9 months after baseline

Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied.

Study Sites (5)

Loading locations...

Similar Trials